Recommendation:
Maintain omaveloxolone as non-preferred on the Practitioner-Managed Prescription Drug Plan (PMPDP) with clinical prior authorization (PA) criteria to ensure medically appropriate use.
Monday, May 15, 2023
New Drug Evaluation: Omaveloxolone Oral Capsules
Drug Use Research & Management Program. Oregon State University. Date of Review: June 2023. Brand Name (Manufacturer): Skyclarys™ (Reata Pharmaceuticals, Inc.).
